Mark N Prichard


Affiliation: University of Alabama at Birmingham
Country: USA


  1. Prichard M, Quenelle D, Hartline C, Harden E, Jefferson G, Frederick S, et al. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother. 2009;53:5251-8 pubmed publisher
  2. Hartline C, Keith K, Eagar J, Harden E, Bowlin T, Prichard M. A standardized approach to the evaluation of antivirals against DNA viruses: Orthopox-, adeno-, and herpesviruses. Antiviral Res. 2018;159:104-112 pubmed publisher
    ..This approach has the potential to accelerate the development of broad spectrum therapies for the DNA viruses. ..
  3. Keith K, Hartline C, Bowlin T, Prichard M. A standardized approach to the evaluation of antivirals against DNA viruses: Polyomaviruses and lymphotropic herpesviruses. Antiviral Res. 2018;159:122-129 pubmed publisher
    ..This analysis helps provide perspective on combinations of agents that would help provide broad coverage of significant pathogens in immunocompromised patients as well as against emerging infections. ..
  4. Britt W, Prichard M. New therapies for human cytomegalovirus infections. Antiviral Res. 2018;159:153-174 pubmed publisher
  5. Prichard M, Keith K, Quenelle D, Kern E. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother. 2006;50:1336-41 pubmed
  6. Prichard M. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19:215-29 pubmed publisher
    ..The critical functions performed by the UL97 kinase illustrate its importance in viral replication and confirm that the kinase is a target for the development of antiviral therapies. ..
  7. Prichard M, Kern E. The search for new therapies for human cytomegalovirus infections. Virus Res. 2011;157:212-21 pubmed publisher
    ..Their antiviral activity both in vitro and in vivo, spectrum of antiviral activity, and mechanism of action will be reviewed to provide an update on the progress of potential new therapies for CMV infections. ..
  8. Prichard M, Williams J, Komazin Meredith G, Khan A, Price N, Jefferson G, et al. Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother. 2013;57:3518-27 pubmed publisher
    ..They also suggest that they might be useful as broad-spectrum antiherpesvirus agents and may be effective in the treatment of resistant virus infections. ..
  9. James S, Prichard M. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance. Curr Opin Virol. 2014;8:54-61 pubmed publisher
    ..This review focuses on currently approved HSV therapies as well as new systemic therapies in development. ..

More Information


  1. Prichard M, Hartline C, Harden E, Daily S, Beadle J, Valiaeva N, et al. Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. Antimicrob Agents Chemother. 2008;52:4326-30 pubmed publisher
    ..The results presented here indicate that HDP-esterified acyclic nucleoside phosphonates with antiviral activity against HIV also inhibit the replication of some herpesviruses and can extend the spectrum of activity for these compounds. ..
  2. Prichard M, Lawlor H, Duke G, Mo C, Wang Z, Dixon M, et al. Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of viral DNA. Virol J. 2005;2:55 pubmed
    ..These data suggest that pUL114 associates with ppUL44 and that it functions as part of the viral DNA replication complex to increase the efficiency of both early and late phase viral DNA synthesis. ..
  3. request reprint
    Prichard M, Williams A, Keith K, Harden E, Kern E. Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus contribute significantly to the differential antiviral activity of nucleoside analogs. Antiviral Res. 2006;71:1-6 pubmed
    ..Additional screening against orthopoxviruses will be required to identify nucleoside analogs that are efficiently activated by their type II TK...
  4. Prichard M, Keith K, Johnson M, Harden E, McBrayer A, Luo M, et al. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother. 2007;51:1795-803 pubmed
    ..This unexpected result suggests that selective phosphorylation by the viral kinase may be a promising new approach in the discovery of highly selective inhibitors of orthopoxvirus replication. ..
  5. Prichard M, Kern E, Quenelle D, Keith K, Moyer R, Turner P. Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine. Virol J. 2008;5:39 pubmed publisher
    ..The recombinant virus is hypersensitive to (N)-methanocarbathymidine and may reflect metabolic differences in the mutant virus. ..
  6. Prichard M, Sztul E, Daily S, Perry A, Frederick S, Gill R, et al. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol. 2008;82:5054-67 pubmed publisher
    ..These data also suggest a potential link between RB function and the formation of aggresomes. ..
  7. Prichard M, Kern E. Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res. 2012;94:111-25 pubmed publisher
    ..Progress that has been achieved in recent years should yield new drugs for the treatment of these infections and might also reveal new approaches for antiviral drug development with other viruses. ..